Pharma RSS Digest - 2026-06-30
Overview
The session leaned on company-specific catalysts rather than broad sector themes. AbbVie and Genmab delivered the day's most commercially significant update, posting a strong Phase 3 win for epcoritamab plus lenalidomide in relapsed/refractory DLBCL. Two regulatory milestones landed stateside and abroad: 4DMedical's non-contrast lung imaging platform secured Australian approval, while Laplace Interventional cleared the FDA hurdle to begin a pivotal tricuspid valve trial. On the financing side, Decoy Therapeutics structured a milestone-heavy PIPE to push its lead antiviral into the clinic. A Class I device recall and small-cap earnings sat just below the key-development threshold.
Key Developments
AbbVie, alongside Genmab, reported that the Phase 3 EPCORE DLBCL-4 trial of epcoritamab plus lenalidomide hit its primary endpoint in relapsed/refractory DLBCL, cutting the risk of progression or death by roughly 60% versus R-GemOx chemoimmunotherapy with a hazard ratio of 0.40 under US censoring. The combination is chemotherapy-free and the trial included patients ineligible for CAR-T or stem-cell transplant, a population with limited effective options. The result strengthens the case for bispecific antibodies moving into earlier relapsed settings and could pressure both CAR-T and competing bispecific franchises. Watch for full data at an upcoming medical meeting, regulatory engagement timelines, and any updates on overall survival and duration of response, which were not in the topline.
4DMedical received TGA approval and ARTG inclusion for its CT:VQ imaging product, adding Australia to a footprint that already spans the US, EU, UK, Canada, and New Zealand. CT:VQ derives ventilation-perfusion mapping from standard non-contrast chest CT, delivered as SaaS that plugs into existing scanner infrastructure, removing the need for radiotracers or nuclear medicine suites. The US install base already includes Stanford, Cleveland Clinic, and SimonMed, among others. The Australian rollout is well-suited to that country's dense CT scanner network. Watch for Medicare reimbursement listings, initial hospital contracts, and any competitive head-to-head data against nuclear V/Q scans.
AbbVie Inc. clinical trial update
Laplace Interventional secured FDA IDE approval for the TRIUMPH pivotal trial of its transcatheter tricuspid valve replacement (TTVR) system in severe tricuspid regurgitation. The randomized arm plans roughly 400 patients across up to 75 sites in a 2:1 comparison against commercial TTVR, with a separate 150-patient registry for patients ineligible for current options. Three global PIs from Mayo Clinic, Vanderbilt, and Providence St. Vincent will lead the study, all drawn from top enrollers in the prior US Early Feasibility Study. The company pegs the US addressable population at over 1.6 million TR patients, though that figure is its own estimate. Watch for first-patient-in timing, primary endpoint disclosure, and any readouts from the feasibility study that haven't yet been published.
Decoy Therapeutics announced a PIPE of up to $21 million from a single healthcare-focused institutional investor, structured as roughly $3.5 million upfront at $5.91 per share plus three milestone-based warrant tranches totaling about $17.5 million. The warrants unlock at successive development gates: an EEA Phase 1 CTA filing, UK MHRA approval of a Phase 2a human challenge trial, and positive Phase 2a data. The structure keeps near-term dilution light but ties roughly 83% of proceeds to clinical and regulatory execution. Proceeds will fund advancement of Decoy's lead antiviral from its IMP³ACT platform. Watch for shareholder approval of the warrant exercises, the EEA CTA filing, and the MHRA interaction on the human challenge trial design.
Decoy Therapeutics, Inc. funding update
Watchlist
- North American Rescue issued a Class I correction for two first aid kit SKUs containing Trividia TRUE METRIX glucose meters, where an ambiguous E-5 error code has been linked to 114 serious injuries and one death; the FDA's April Safety Communication still applies. [link]
- SchistoShield, TTUHSC's Sm-p80 plus GLA-SE schistosomiasis vaccine, showed robust T-cell and B-cell memory in small Phase I/1b trials; larger efficacy studies are the next milestone. [link]
- Devonian Health Group posted a narrower Q3 net loss of $1.9M (CAD) largely due to a prior-year impairment, but cash fell to $0.7M against $8.4M of operating burn, pointing to additional financing needs as it advances Thykamine in radiodermatitis and pediatric atopic dermatitis. [link]